摘要:
An agent for susceptive diseases, which contains a polypeptide that has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing, strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human at a relatively-high dose. The agent treats and/or prevents malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases including atopies.
摘要:
A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-γ, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.
摘要:
A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-γ, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.
摘要:
A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-γ, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.
摘要:
A physiologically active extract comprising an ethyl acetate-soluble ingredient of an indigo plant, which is obtainable by soaking a raw indigo plant in an organic solvent used for extraction. The ethyl acetate-soluble ingredient includes tryptanthrin, 3,5,4′-trihydroxy-6,7-methylenedioxy-flavone, kaempferol, 3,5,7,4′-tetrahydroxy-6-methoxy-flavone, gallic acid, caffeic acid, indirubin, pheophorbide a, and methylpheophorbide a.
摘要:
A novel melanin formation-inhibitory protein, which has a molecular weight of 90,000.+-.20,000 and a pI of 5.5.+-.0.5, exerts a tyrosinase formation-inhibitory activity in pigment cells but does not substantially inhibit the inherent tyrosinase activity. Thus, the protein is advantageously used as a pharmaceutical and as a cosmetic in the prevention and/or treatment for local chromatosises such as chloasma, ephelis and sunburn, as well as for systemic chromatosises such as addisonism.
摘要:
The objects of the present invention are to provide a method for inhibiting the coloration of a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, without deteriorating the taste inherent to the syrupy sweetener; and to provide a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which is stabilized by the method. The present invention attains the above objects by providing a method for inhibiting the coloring of a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which comprises a step of incorporating a lactate into the syrupy sweetener, and by providing a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which is stabilized by the method.
摘要:
The present invention has objects to provide a thermostable cellobiose 2-epimerase, its preparation and uses. The present invention attains the above objects by providing a thermostable cellobiose 2-epimerase, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a process for producing the enzyme, and a process for producing isomerized saccharides using the enzyme.
摘要:
The object of the present invention is to provide a method and a process for producing 2-O-α-glucopyranosyl-L-ascorbic acid where 5-O-α-glucopyranosyl-L-ascorbic acid and 6-O-α-glucopyranosyl-L-ascorbic acid are not formed or formed in such a small amount that the formation of these can nor be detected. The present invention solves the above object by providing a process for producing 2-O-α-glucopyranosyl-L-ascorbic acid comprising the steps of allowing α-isomaltosyl glucosaccharide-forming enzyme together with or without cyclomaltodextrin glucanotransferase (EC 2.4.1.19) to act on a solution comprising L-ascorbic acid and, an α-glucosyl saccharide to form 2-O-α-glucopyranosyl-L-ascorbic acid and collecting the formed 2-O-α-glucopyranosyl-L-ascorbic acid.
摘要:
The present invention has an object to provide an external dermal agent with a sustainable anti-wrinkle action, which has both the action of enhancing the proliferation and differentiation of keratinocytes in the skin and the action of enhancing the collagen production in the skin, and which assists the maintenance and the improvement of tissue structures and physiological functions of the epidermis and the dermis, whereby providing a remarkable skin improvement effect. The present invention solves the above abject by providing an external dermal agent containing α-D-glucopyranosyl-(1→3′)-adenosine and/or α-D-glucopyranosyl-(1→5′)-adenosine as an effective ingredient(s).